Top Markets
#1 Trillions Trillions +4,372.14%
#2 Ozapay Ozapay +38.75%
#3 Aria.AI Aria.AI +21.09%
#4 TRIA TRIA +14.07%
#5 Zano Zano +12.87%
#6 Osaka Protocol Osaka Protocol +11.93%
#7 DeXe DeXe +11.67%
#8 River Pts River Pts +11.61%
#9 pippin pippin +11.02%
#10 StakeStone StakeStone +10.06%
Coin of the day
Trillions Trillions
Settings
Language
ENGLISH
Currency
USD
Theme
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rank in Stocks #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Share Price
$0.28545656
Market Cap
$4.50M
Change (1 day)
5.97%
Change (1 year)
0.00%
Country
FR
Trade Acticor Biotech SAS (ALACT)

Category

Healthcare
Number of shares outstanding for Acticor Biotech SAS (ALACT)
Number of shares outstanding as of June 2024: 15.76M
According to Acticor Biotech SAS latest financial reports and stock price the company's current number of shares outstanding is 15.76M. At the end of December 2022 the company had 10.55M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Acticor Biotech SAS (ALACT) from 2010 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 15.76M 30.55%
2023 12.07M 14.44%
2022 10.55M 35.54%
2021 7.78M 22.37%
2020 6.36M 21.38%
2019 5.24M 70.67%
2018 3.07M -7.38%
2017 3.31M 0.00%
2016 3.31M 0.00%
2015 3.31M 0.00%
2014 3.31M 0.00%
2013 3.31M 0.71%
2012 3.29M 0.00%
2011 3.29M -34.01%
2010 4.99M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 28,130.95%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 1,511.53%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M 553.12%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M 1,105.93%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 2,969.30%
AU